Clinical trial
A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects…
NCT01767311 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT01767311 |
|---|---|
| Title | A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease |
| Official title | A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease |
| Lead sponsor | Eisai Inc., Industry |
| Collaborators | Biogen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Lecanemab 2.5 mg/kg, Lecanemab 5.0 mg/kg, Lecanemab 10 mg/kg, Placebo |
| Enrollment | 856 |
| Start date | Dec 20, 2012 |
| Primary completion | Dec 10, 2024 |
| Completion | Dec 10, 2024 |
| First posted | Jan 14, 2013 |
| Last update posted | Jan 22, 2025 |
| Countries | Canada, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, Sweden, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: